Motley Fool Inside Value pick Pfizer (NYSE: PFE) closed the chapter on its inhalable insulin experiment with Nektar Therapeutics (Nasdaq: NKTR) today. In exchange for giving Nektar $135 million in cash, Pfizer no longer has to market Exubera.Pfizer’s marketing of Exubera has been a total disaster since its approval in January 2005. Insurers were unwilling to pay for the drug, and national health-care authorities, for example in the U.K., limited its use to only a small subset of diabetes patients. Sales of the drug were only $12 million in the first nine months of 2007.
